卵巢癌市场:KOL的洞察

本报告提供全球卵巢癌市市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

已上市产品

• PARPis
  • PARPis(Lynparza，Rubraca，Zejula)相关洞察
  • LYNPARZA(oraparibu，AstraZeneca/Merck & Co.)
  • Rubraca(rukaparibu，Clovis Oncology)
  • zejura(niraparibu，GSK)
• ADC/管磷抑制剂
  • ADC/管磷抑制剂相关洞察
  • Elahere(mirubetsukishimabusorafutanShinn，ImmunoGen)

开发中产品

• 免疫查核点抑制剂(ICI)
  • ICI级相关洞察
  • babenshio(Avelumab，Merck Group)
  • imifinji(Durvalumab、 AstraZeneca)
  • jenperi(dosutarimabu，GSK)
  • KEYTRUDA(Pembrolizumab，Merck &Co.)
  • Opdivo/yaboi(Nivolumab/Ipilimumab，BMS/小野)
  • TECENTRIQ(Atezolizumab，Roche)
• 治疗用疫苗
  • oregobomabu(抗个体遗传型mAb，OncoQuest)
  • Olvi-Vec(olvimulogene nanivacirepvec，Genelux Corporation)
  • 装载Vigil(Bi-shRNAfurin-GM-CSF的癌细胞疫苗，Gradalis)
• 其他的后期阶段的治疗方法
  • UpRi(upifitamaburirusodochin，Adimab/Mersana Therapeutics)
  • Batiraxcept(GAS6-AXL途径抑制剂，Aravive)
• 糖皮质激素受体拮抗剂
  • Korlym(rirakoriranto，Corcept Therapeutics)
  • 肿瘤治疗领域(TTF，Novocure)
• 中期及初期阶段的模式
  • 下一代ADC以及其他的MOA
  • AZD 1775/MK 1775(adaboseruchibu，Merck & Co/AstraZeneca)
  • AZD 8205( AstraZeneca)
  • enherutsu(Trastuzumabderukusutekan、 AstraZeneca/第一三共)
  • IMGN 151(ImmunoGen)
  • MK-4830(Merck & Co)
  • REGN 4018(ubatamamabu，Regeneron)
  • SKB 264/MK-2870(Merck & Co)
  • STRO-002(ruberutamabutazebiburin，Sutro Biopharma)
  • VS-6766(automechinibu，Verastem Oncology)

附录

Readouts of AstraZeneca's DUO-O positive study demonstrated significantly improved progression free survival - so why do KOLs doubt it will be practice changing? Experts are excited by the potential of ImmunoGen's ADC Elahere, but what safety concerns could impact its uptake? What factors underpin the prescribing of AstraZeneca/Merck & Co's Lynparza and GSK's Zejula PARP inhibitors? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (5)

Current and future treatment algorithm

Research objectives (2)

Marketed products (28)

• PARPis (14)
  • Insights for the PARPis (Lynparza, Rubraca, Zejula) (3)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (1)
  • Rubraca (rucaparib; Clovis Oncology) (1)
  • Zejula (niraparib; GSK) (9)
• ADC/tubulin inhibitors (14)
  • Insights for the ADC/tubulin inhibitor (3)
  • Elahere (mirvetuximab soravtansine; ImmunoGen) (11)

Pipeline products (78)

• Immune checkpoint inhibitors (ICI) (15)
  • Insights for the ICI class (3)
  • Bavencio (avelumab; Merck Group) (1)
  • Imfinzi (durvalumab; AstraZeneca) (1)
  • Jemperli (dostarlimab; GSK) (1)
  • Keytruda (pembrolizumab; Merck & Co.) (1)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono) (1)
  • Tecentriq (atezolizumab; Roche) (7)
• Therapeutic vaccines (22)
  • Oregovomab (anti-idiotype mAb; OncoQuest) (10)
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation) (6)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis) (6)
• Other late-stage modalities (14)
  • UpRi (upifitamab rilsodotin; Adimab/Mersana Therapeutics) (7)
  • Batiraxcept (GAS6-AXL pathway inhibitor; Aravive) (7)
• Glucocorticoid receptor antagonists (11)
  • Korlym (relacorilant; Corcept Therapeutics) (7)
  • Tumour treating fields (TTFs; Novocure) (4)
• Mid and early-stage modalities (16)
  • Next-generation ADCs and other MOAs (2)
  • AZD 1775/MK 1775 (adavosertib; Merck & Co/AstraZeneca) (1)
  • AZD 8205 (AstraZeneca) (1)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo) (1)
  • IMGN 151 (ImmunoGen) (1)
  • MK-4830 (Merck & Co) (1)
  • REGN 4018 (ubamatamab; Regeneron) (1)
  • SKB 264/MK-2870 (Merck & Co) (1)
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma) (1)
  • VS-6766 (avutometinib; Verastem Oncology) (6)

Appendix (4)

• KOL details (4)
  • KOLs from the US (1)
  • KOLs from Europe (2)